CD44 and Familial prostate cancer: In a study investigating the differences in glucose metabolism between two forms of prostate cancer, small cell neuroendocrine carcinoma (SCNC) was found to be more glycolytic than adenocarcinoma, CD44 being a key regulator of glucose metabolism.